angiotensin II receptor antagonist

(redirected from Angiotensin II receptor antagonists)

angiotensin II receptor antagonist

Any of a family of agents (e.g., losartan and valsartan) that block the binding of angiotensin II (A-II) to their cognate cell receptors—AT1, AT2 and others. First-generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains to block the binding of A-II to AT1.

ARAs are an alternative to ACEI therapy in patients with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference of which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.

angiotensin II receptor antagonist

Pharmacology Any of a family of agents-eg losartan and valsartan, which block the binding of angiotensin II–A-II to its cognate cell membrane receptors–AT1, AT2, and others; 1st generation ARAs included the sartan family of agents, which only block AT1, interacting with the amino acids in the transmembrane domains, blocking the binding of A-II to AT1; an alternative to ACEI therapy for Pts with CHF; unlike ACEIs, ARAs do not interfere with bradykinin and prostaglandin metabolism, interference which has been linked to some of the adverse effects of ACEI therapy, particularly to cough and angioedema.
References in periodicals archive ?
The FOCUS study, a randomized, double-blind, parallel-group, placebo controlled study, evaluated the efficacy of two dosing regimens of fremanezumab in a large population of adult patients with episodic or chronic migraine who had documented prior inadequate response within the past ten years to two-to-four pharmacological classes of migraine preventive medications: beta blockers, anticonvulsants, tricyclic antidepressants, calcium channel blockers, angiotensin II receptor antagonists, onabotulinumtoxinA, or valproic acid.
In addition, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARAs), and endothelin receptor antagonists (ERAs) have been used for antihypertensive therapy over the past 20 years [12,13].
In nonpregnant women, angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists are popular first-line therapies for primary hypertension.
Feng Y, Biocompatible in-Tube Solid-Phase Microextraction Coupled to HPLC for the Determination of Angiotensin II Receptor Antagonists in Human Plasma and Urine, J.
Irbesartan is an effective antihypertensive agent belonging to the category of angiotensin II receptor antagonists. Liver injury has been reported with irbesartan and other members of this group.
Neuroprotective effects of antihypertensive medication are achieved by angiotensin-converting enzyme inhibitors and diuretics, according to some authors (3), but also by angiotensin II receptor antagonists and dihydropiridines, according to other authors (4).
Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxyliv acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
These include ACE inhibitors, such as Altace (ramipril), and angiotensin II receptor antagonists, such as Diovan (valsartan).
Sharma, "Molecular modelling studies of some substitued 2-butylbenzimidazoles angiotensin II receptor antagonists as antihypertensive agents," Digest Journal of Nanomaterials and Biostructures, vol.
Whereas, the exclusion criteria included patients having a current diagnosis of type 1 or type 2 diabetes mellitus, patients on antihypertensive therapy or any drug that affects blood pressure, patients with a history of hepatic, cardiac, renal or blood diseases or other diseases which may interfere with the study, patients having hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, patients with a history of severe or resistant hypertension, patients with secondary hypertension of any etiology, pregnant or breast feeding women, and patients with serious disorders which may limit the ability to evaluate the efficacy of the trial drugs.

Full browser ?